FORTUNE -- Every smart investors knows you should aim to buy low and sell high, so why is the concept lost on managers of public companies?
As Will Becker, analyst at Behind the Numbers, shows in a new report to clients on the trend of increased share buybacks, when company management buys back its own stock, it tends to do it when market valuations are high, not low. And that's exactly what's happened over the past year as the S&P 500 repeatedly reached new heights.
According to data assembled by Becker, S&P 500 companies increased the total dollar amount of share buybacks they engaged in by 28.5% year-over-year in the fourth quarter of 2013, to $126 billion. "While this represents a sequential increase of just 1.7% from 3Q13, S&P 500 companies have been more active over the trailing twelve months ended 12/31/13 than in any period since the financial crisis," he writes.
A few more stats from Becker's report:
Defenders of share buyback schemes often point to the fact that a buyback can help companies and investors reduce their tax liabilities. For instance, a company can borrow money to repurchase shares and deduct the interest paid on debt. At the same time, some investors would rather their investments appreciate through share buybacks than receive a dividend because they must immediately pay taxes on dividends but not gains on stock they haven't sold.
Others argue that share repurchases should be a natural step in a company's lifecycle. Firms competing in declining industries with few good capital investment options must find a way to return profits to their shareholders, and share buybacks are an effective way to wind down a struggling company in a way that keeps shareholders and executives happy.
But what about companies operating in arguably thriving industries, like pharmaceuticals, that will only grow more profitable as the population within wealthy nations ages? In his report, Becker fingers pharma company Pfizer (PFE) as one such firm with few good excuses for buying back so many of its shares. Pfizer has been hit hard by the expiration of patents on two of its best-selling drugs, Lipitor and Viagra, in recent years, and it has been, according to Becker, "scrambling" to replace that revenue with cost cutting, acquisitions, and restructuring of its R&D efforts.
But instead of pouring its profits into developing new drugs, Pfizer has been busy buying back huge amounts of its own stock -- $16.3 billion worth in 2013. Becker argues that the company's move may have as much to do with executives hoping to reduce the total number of shares in circulation so that they can meet certain stock-price based performance metrics as it has to do with the belief that Pfizer shares are undervalued. Writes Becker:
Looking at PFE's annual incentive program, a pool is funded based on the company's performance on three financial metrics: total revenue, adjusted diluted earnings per share and cash flow from operations ... largely with the aid of its record share repurchase activity, PFE managed to exceed the 2013 target goal fro adjusted diluted EPS, while producing slightly below-target performance for its revenue and cash flow metrics.
While Pfizer didn't have a particularly stellar 2013, its executives still received healthy bonuses, in part because Pfizer surpassed its goals for growth in earnings per share, a goal that wouldn't have been met without such a concerted effort to keep the total number of shares outstanding low. Meanwhile, Pfizer has reduced its investment in research and development as a percentage of revenue every year since 2007 -- which can't bode well for the company's prospects of launching the next Lipitor or Viagra.
Becker believes Autozone (AZO) is also a bit too fond of share buybacks and that its CEO William Rhodes stands to be a chief beneficiary of the strategy, as "a material amount of his future compensation is tied to diluted EPS targets." Like Pfizer, the money to buy back shares has forced Autozone to reduce investment elsewhere in the company as it has recently reported a cash flow deficit and has had to take on hundreds of millions of dollars in new debt.
Becker also points to companies like Sysco (SYY), Jarden (JAH), and Brinker International (EAT) as firms buying back for the wrong reasons, but there are surely many more out there. And as the stock market continues to rise, investors should be ever more wary of investing in companies that would rather buy back shares of their own stock at high valuations than invest in its business, the ostensible generator of capital gains.
A pair of moves by the Internet giant proves complicated financial transactions are still alive and well.
FORTUNE -- Wall Street deals haven't gotten any less convoluted since the financial crisis. We got some more evidence of that this week.
On Tuesday night, Yahoo announced it was raising $1 billion and at the same time buying back $5 billion worth of its own stock. Reporters covering the deal focused on the MOREStephen Gandel, senior editor - Nov 22, 2013 7:00 AM ET
Why it's more important than ever to focus on the dividends and buybacks that companies return to shareholders.
FORTUNE -- Dividend-paying stocks have generated intense debate in recent years. Has the rising market made their prices too high and their yields too low -- or is a dividend-heavy portfolio still the best way to garner superior returns? For Chris Brightman, that discussion misses the point. Brightman is the head of investment MOREShawn Tully, senior editor-at-large - Feb 14, 2013 5:00 AM ET
That's what most companies do when they buy their own shares. But you can avoid the trap.
FORTUNE -- In 2006 and 2007 timber giant Weyerhaeuser (WY) conducted one of the biggest share buybacks in its history. It unleashed $800 million to purchase its shares, which were dancing near an all-time high of $80. In 2009, with the stock at $30, the company spent a mere $2 million on its own MOREScott Cendrowski, writer - Jul 11, 2011 5:00 AM ET
Who is most eager to put the AIG bailout in the rearview mirror?
The government would certainly like to sell off its holdings in the giant insurer sooner rather than later. Witness its decision to sell a big chunk of AIG (AIG) shares this spring even with the stock down sharply from its level at the end of 2010.
But AIG chief Bob Benmosche makes clear in the video below that he MOREColin Barr - Jun 22, 2011 4:21 PM ET
Are struggling department stores sitting on a real estate gold mine?
Wall Street certainly hopes so, judging by Thursday's furious rally in shares of Dillard's (DDS) and the smaller gains in JCPenney (JCP) and the biggest laggard of them all, Sears Holdings (SHLD).
Dillard's surged 17%, JCPenney 6% and Sears 5% after Arkansas-based Dillard's said it intends to set up a real estate investment trust that will allow it to borrow against MOREColin Barr - Jan 20, 2011 11:00 AM ET
JPMorgan Chase expects to start raising its dividend early next year, CEO Jamie Dimon will tell investors this afternoon.
Dimon (right) is scheduled to appear this afternoon at the Barclays Global Financial Services conference in New York. "We intend to restore the dividend," presentation materials posted on JPMorgan's (JPM) web site say, "hopefully early 2011."
The comments are in line with the remarks Dimon has made over the past year, as investors have asked when MOREColin Barr - Sep 14, 2010 12:24 PM ET
Intel's (INTC) lessons for Apple (AAPL).
Bond funds cost too damn much.
Dallas Fed researchers deem a double dip unlikely.
Buybacks don't work, for crying out loud.
In for a Penny, in for a pound.Colin Barr - Jul 16, 2010 4:25 PM ET
|Regulators pave way for Internet "fast lane" with net neutrality rules|
|What stumps Warren Buffett? Minimum wage|
|Analysts offer no apologies for missing Apple's Q2 2014 earnings beat|
|Facebook profit triples on mobile growth|
|Apple shares soar on increased buyback|